V. V. Karaseva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
V. V. Karaseva has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- A. V. Fateeva
Pacific State Medical University; Khimki Clinical Hospital
3 shared publications - Alexey A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - Dmitry A. Nosov
Central Clinical Hospital with Polyclinic of the Administrative Department of the President of the Russian Federation
3 shared publications - Sergei A. Tjulandin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - A. Z. Isyangulova
Prof. M. Z. Sigal Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Tatarstan
2 shared publications - A.A. Plykina
Russian Society of Clinical Oncology
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (2) , 108-114
Resolution on the results of the expert council on the topic “Diagnosis and treatment of advanced non-small cell lung cancer with BRAF mutation: from the search for molecular targets to therapeutic strategies in real-world clinical practice”
On January 27, 2026, an Advisory Board was held to discuss issues of molecular genetic diagnosis of the BRAF V600E mutation in patients with advanced non-small cell lung cancer (NSCLC), as well as current treatment options for NSCLC patients with the BRAF V600E mutation. Next generation sequencing (NGS) is the most sensitive and specific method for molecular genetic testing. Its implementation in routine clinical practice will improve the detection rate of BRAF positive NSCLC patients. The accepted standard of care for patients with advanced NSCLC and the BRAF V600E mutation is targeted therapy with BRAF / MEK inhibitors. In the Russian Federation, the combination of dabrafenib and trametinib is approved for use. At the Advisory Board, results were presented from a study of a new targeted combination: encorafenib (a BRAF inhibitor) and binimetinib (a MEK inhibitor). In the Phase II PHAROS clinical trial, the encorafenib — binimetinib combination demonstrated a high rate and durability of antitumor response in adult patients with advanced NSCLC and the BRAF V600E mutation. The objective response rate in treatment naive and previously treated patient groups was 75 % and 49 %, respectively. The median progression free survival (PFS) in the subgroups was 30.4 months and 9.3 months, respectively. At the time of publication, the indication “advanced NSCLC with the BRAF V600E mutation” for the targeted drug combination of encorafenib and binimetinib has not been registered in the Russian Federation.
- 28 August 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (2) , 108-114
Open AccessResolution on the results of the expert council on the topic “Diagnosis and treatment of advanced non-small cell lung cancer with BRAF mutation: from the search for molecular targets to therapeutic strategies in real-world clinical practice”
On January 27, 2026, an Advisory Board was held to discuss issues of molecular genetic diagnosis of the BRAF V600E mutation in patients with advanced non-small cell lung cancer (NSCLC), as well as current treatment options for NSCLC patients with the BRAF V600E mutation. Next generation sequencing (NGS) is the most sensitive and specific method for molecular genetic testing. Its implementation in routine clinical practice will improve the detection rate of BRAF positive NSCLC patients. The accepted standard of care for patients with advanced NSCLC and the BRAF V600E mutation is targeted therapy with BRAF / MEK inhibitors. In the Russian Federation, the combination of dabrafenib and trametinib is approved for use. At the Advisory Board, results were presented from a study of a new targeted combination: encorafenib (a BRAF inhibitor) and binimetinib (a MEK inhibitor). In the Phase II PHAROS clinical trial, the encorafenib — binimetinib combination demonstrated a high rate and durability of antitumor response in adult patients with advanced NSCLC and the BRAF V600E mutation. The objective response rate in treatment naive and previously treated patient groups was 75 % and 49 %, respectively. The median progression free survival (PFS) in the subgroups was 30.4 months and 9.3 months, respectively. At the time of publication, the indication “advanced NSCLC with the BRAF V600E mutation” for the targeted drug combination of encorafenib and binimetinib has not been registered in the Russian Federation.
- 18 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (3) , 7-14
HER2 status assessment in carcinomas of various localizations. A multicenter morphological study in the Russian Federation
HER2 is a clinically significant predictive and prognostic marker in a number of epithelial malignant neoplasms. With the introduction of HER2-targeted therapeutic approaches, including antibody-drug conjugates, the need for standardized assessment of HER2 status in tumors of various localizations has become increasingly important. Objective. To assess the prevalence of HER2-positive tumors (IHC 3+) in epithelial malignant neoplasms of various localizations in the Russian population using a unified diagnostic approach. Material and methods. This multicenter study included 1.511 tumor tissue samples from patients with epithelial malignant neoplasms of various localizations, obtained from reference pathology centers of the Russian Federation. HER2 status was determined by immunohistochemistry using anti-HER2 antibody (clone 4B5, Ventana) and standardized interpretation criteria developed for gastric cancer and gastroesophageal junction cancer. In cases of equivocal HER2 status (IHC 2+), in situ hybridization was recommended. Results. HER2-positive tumors (IHC 3+) were identified in the majority of the analyzed localizations, with prevalence varying widely depending on tumor type. The highest frequency of HER2 positivity was observed in urothelial carcinoma of the urinary bladder, as well as in gastric and gastroesophageal junction cancers. No HER2-positive cases were detected in lung adenocarcinoma or pancreatic cancer. Conclusion. The study results confirm the reproducibility of HER2 status assessment using a unified diagnostic approach in a multicenter setting. The application of standardized HER2 interpretation criteria ensures data comparability and provides a methodological basis for further clinicopathological studies and for the implementation of HER2-targeted therapeutic strategies in clinical practice.
- 18 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (3) , 7-14
HER2 status assessment in carcinomas of various localizations. A multicenter morphological study in the Russian Federation
HER2 is a clinically significant predictive and prognostic marker in a number of epithelial malignant neoplasms. With the introduction of HER2-targeted therapeutic approaches, including antibody-drug conjugates, the need for standardized assessment of HER2 status in tumors of various localizations has become increasingly important. Objective. To assess the prevalence of HER2-positive tumors (IHC 3+) in epithelial malignant neoplasms of various localizations in the Russian population using a unified diagnostic approach. Material and methods. This multicenter study included 1.511 tumor tissue samples from patients with epithelial malignant neoplasms of various localizations, obtained from reference pathology centers of the Russian Federation. HER2 status was determined by immunohistochemistry using anti-HER2 antibody (clone 4B5, Ventana) and standardized interpretation criteria developed for gastric cancer and gastroesophageal junction cancer. In cases of equivocal HER2 status (IHC 2+), in situ hybridization was recommended. Results. HER2-positive tumors (IHC 3+) were identified in the majority of the analyzed localizations, with prevalence varying widely depending on tumor type. The highest frequency of HER2 positivity was observed in urothelial carcinoma of the urinary bladder, as well as in gastric and gastroesophageal junction cancers. No HER2-positive cases were detected in lung adenocarcinoma or pancreatic cancer. Conclusion. The study results confirm the reproducibility of HER2 status assessment using a unified diagnostic approach in a multicenter setting. The application of standardized HER2 interpretation criteria ensures data comparability and provides a methodological basis for further clinicopathological studies and for the implementation of HER2-targeted therapeutic strategies in clinical practice.
- Open Access
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 18-28
What we know about the new coronavirus infection in cancer patients
The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 18-28
Open AccessWhat we know about the new coronavirus infection in cancer patients
The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.
- Open Access
- 22 December 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 104-112
Genomic characteristics of Russian patients with non-small cell lung cancer: Results of next-generation sequencing testing
Introduction. Next-generation sequencing (NGS) is a molecular approach that can provide clinicians with comprehensive information about a patient’s molecular profile, which is an important aspect of the effective application of targeted therapy.Aim. To assess the frequency of tumor somatic mutations in non-small cell lung cancer (NSCLC) in a cohort of Russian patients to subsequently optimize diagnostics and personalize treatment strategies.Materials and methods. The study included the results of NGS testing from a cohort of 1.400 NSCLC patients between March 17, 2023, and July 22, 2024. Several other clinics across the country participated in this multicenter study. Panels with various options for identifying potential genetic alterations were used. An analysis of the frequency of various alterations was conducted based on the panel used, clinical characteristics of the patients, considering the geographical and ethnographic diversity of the regions in the country.Results. Mutations were most frequently found in the KRAS (17.9%) and EGFR (15.8%) genes, particularly among never-smoker women. The frequency of rare mutations such as RET, MET, and NTRK corresponds to literature data and underscores the need to expand the group of patients being tested for these alterations. However, deletions in exon 19 of EGFR (12.7%) and KRAS G12C (16.4%) were also found among smokers. The results highlight the inadequate scope of existing testing, partly due to the lack of co-mutation assessment and primary resistance mutations, while also demonstrating possible differences when using various diagnostic panels.Conclusion. The implementation of NGS in public health systems allows for a more personalized approach to selecting treatment strategies for patients. The data obtained can be used in predictive models to optimize drug distribution.
- 22 December 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 104-112
Open AccessGenomic characteristics of Russian patients with non-small cell lung cancer: Results of next-generation sequencing testing
Introduction. Next-generation sequencing (NGS) is a molecular approach that can provide clinicians with comprehensive information about a patient’s molecular profile, which is an important aspect of the effective application of targeted therapy.Aim. To assess the frequency of tumor somatic mutations in non-small cell lung cancer (NSCLC) in a cohort of Russian patients to subsequently optimize diagnostics and personalize treatment strategies.Materials and methods. The study included the results of NGS testing from a cohort of 1.400 NSCLC patients between March 17, 2023, and July 22, 2024. Several other clinics across the country participated in this multicenter study. Panels with various options for identifying potential genetic alterations were used. An analysis of the frequency of various alterations was conducted based on the panel used, clinical characteristics of the patients, considering the geographical and ethnographic diversity of the regions in the country.Results. Mutations were most frequently found in the KRAS (17.9%) and EGFR (15.8%) genes, particularly among never-smoker women. The frequency of rare mutations such as RET, MET, and NTRK corresponds to literature data and underscores the need to expand the group of patients being tested for these alterations. However, deletions in exon 19 of EGFR (12.7%) and KRAS G12C (16.4%) were also found among smokers. The results highlight the inadequate scope of existing testing, partly due to the lack of co-mutation assessment and primary resistance mutations, while also demonstrating possible differences when using various diagnostic panels.Conclusion. The implementation of NGS in public health systems allows for a more personalized approach to selecting treatment strategies for patients. The data obtained can be used in predictive models to optimize drug distribution.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (4)
Cost of supportive cancer care in the Russian Federation. Part 2
Objective. To assess the cost of supportive drug therapy for 10 complications of malignant neoplasms according to the recommendations of the Russian Public Organization «Russian Society of Clinical Oncology» (RUSSCO). Material and methods. Considering the RUSSCO recommendations, we estimated drug therapy regimens for the following complications: anemia, hepatotoxicity, dermatological reactions, cardiovascular toxicity, neurological complications, nephrotoxicity, effects of extravasation, febrile neutropenia, nausea and vomiting, central venous access. To estimate the population requiring supportive therapy, we used data from registers of medical care bills for 2022. These reports contain information on the number of completed cases of antitumor drug therapy and the number of patients who received treatment. Literature data on the incidence of the above-mentioned complications were also used. Results. The largest financial costs (63.8% of all complications) were observed for the treatment of anemia (4 721 896 721.06 rubbles), hepatotoxicity (3 545 843 422.82 rubbles) and consequences of extravasation (2 388 137 692.57 rubbles). The oncology profile accounts for 66% of the estimated funding within this model. In the current model, 34% of the need is for preferential drug provision, 37% is additional need for compulsory medical insurance to finance the added cost of hospital-stay in a day hospital and 31% in a 24-hour hospital. Conclusion. These findings complement the previously published results for other complications presented in the RUSSCO recommendations. Calculation methodology and appropriate data can underlie further improvement of financing of supportive cancer therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (4)
Cost of supportive cancer care in the Russian Federation. Part 2
Objective. To assess the cost of supportive drug therapy for 10 complications of malignant neoplasms according to the recommendations of the Russian Public Organization «Russian Society of Clinical Oncology» (RUSSCO). Material and methods. Considering the RUSSCO recommendations, we estimated drug therapy regimens for the following complications: anemia, hepatotoxicity, dermatological reactions, cardiovascular toxicity, neurological complications, nephrotoxicity, effects of extravasation, febrile neutropenia, nausea and vomiting, central venous access. To estimate the population requiring supportive therapy, we used data from registers of medical care bills for 2022. These reports contain information on the number of completed cases of antitumor drug therapy and the number of patients who received treatment. Literature data on the incidence of the above-mentioned complications were also used. Results. The largest financial costs (63.8% of all complications) were observed for the treatment of anemia (4 721 896 721.06 rubbles), hepatotoxicity (3 545 843 422.82 rubbles) and consequences of extravasation (2 388 137 692.57 rubbles). The oncology profile accounts for 66% of the estimated funding within this model. In the current model, 34% of the need is for preferential drug provision, 37% is additional need for compulsory medical insurance to finance the added cost of hospital-stay in a day hospital and 31% in a 24-hour hospital. Conclusion. These findings complement the previously published results for other complications presented in the RUSSCO recommendations. Calculation methodology and appropriate data can underlie further improvement of financing of supportive cancer therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Cost of supportive cancer care in the Russian Federation. Part 1
Objective. Modeling of annual cost of supportive therapy for malignant neoplasms in accordance with the guidelines of the All-Russian public organization “Russian Society of Clinical Oncology” (RUSSCO). Material and methods. The main material for modelling the cost of treatment were drug regimens presented in the RUSSCO guidelines for the following complications: chronic viral hepatitis B, hormone-mediated side effects, bone tissue pathology, immune-mediated side effects, mucositis, infusion reactions, thromboembolic complications, chronic pain syndrome, anorexia-cachexia syndrome, as well as enzyme replacement therapy for pancreatic cancer and nutritional support. To calculate population receiving anticancer drug therapy, we used data on medical billing registry database (2022). This database contains information on the number of completed cases of anticancer drug therapy and the number of appropriate patients. During the modeling, we hypothetically divided financing depending on the profiles of medical care and sources of funding. Results. The most expensive cases (87.2% of overall requirement) are treatment of bone lesions (5.532.288.615.94 rubles), thromboembolic complications (5.973.880.025.31 rubles), chronic pain syndrome (6.309.163.258.86 rubles) and nutritional support (7.009.301.585.00 rubles). Approximately 75% of the estimated funding is for «oncology» profile, i.e. treatment of complications will take place during chemotherapy period. In the current model, 47% of funding goes from the state programs of free drug supply, 28% from compulsory medical insurance to cover stay at the day and 24-hour hospitals, 23% from personal patients’ expenses. Conclusion. Modeling of supportive cancer therapy cost can underlie changes in medical care payment system.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Cost of supportive cancer care in the Russian Federation. Part 1
Objective. Modeling of annual cost of supportive therapy for malignant neoplasms in accordance with the guidelines of the All-Russian public organization “Russian Society of Clinical Oncology” (RUSSCO). Material and methods. The main material for modelling the cost of treatment were drug regimens presented in the RUSSCO guidelines for the following complications: chronic viral hepatitis B, hormone-mediated side effects, bone tissue pathology, immune-mediated side effects, mucositis, infusion reactions, thromboembolic complications, chronic pain syndrome, anorexia-cachexia syndrome, as well as enzyme replacement therapy for pancreatic cancer and nutritional support. To calculate population receiving anticancer drug therapy, we used data on medical billing registry database (2022). This database contains information on the number of completed cases of anticancer drug therapy and the number of appropriate patients. During the modeling, we hypothetically divided financing depending on the profiles of medical care and sources of funding. Results. The most expensive cases (87.2% of overall requirement) are treatment of bone lesions (5.532.288.615.94 rubles), thromboembolic complications (5.973.880.025.31 rubles), chronic pain syndrome (6.309.163.258.86 rubles) and nutritional support (7.009.301.585.00 rubles). Approximately 75% of the estimated funding is for «oncology» profile, i.e. treatment of complications will take place during chemotherapy period. In the current model, 47% of funding goes from the state programs of free drug supply, 28% from compulsory medical insurance to cover stay at the day and 24-hour hospitals, 23% from personal patients’ expenses. Conclusion. Modeling of supportive cancer therapy cost can underlie changes in medical care payment system.